Prognostic significance of CD163+ tumor-associated macrophages in colorectal cancer.

Szczegóły
Abstrakt

Tytuł:: Prognostic significance of CD163+ tumor-associated macrophages in colorectal cancer.
Autorzy:: Xue T; Department of Traumatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang Province, China.
Yan K; Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.
Cai Y; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, No. 1 West Fanhai Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China.
Sun J; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, No. 1 West Fanhai Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China.
Chen Z; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, No. 1 West Fanhai Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China.
Chen X; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, No. 1 West Fanhai Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China.
Wu W; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, No. 1 West Fanhai Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China. .
Źródło:: World journal of surgical oncology [World J Surg Oncol] 2021 Jun 24; Vol. 19 (1), pp. 186. Date of Electronic Publication: 2021 Jun 24.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: London : BioMed Central, 2003-
MeSH Terms:: Colorectal Neoplasms*
Tumor-Associated Macrophages*
Antigens, CD ; Antigens, Differentiation, Myelomonocytic ; Humans ; Macrophages ; Prognosis ; Receptors, Cell Surface
References:: Cancer Sci. 2019 Dec;110(12):3639-3649. (PMID: 31605436)
World J Surg Oncol. 2019 May 22;17(1):85. (PMID: 31118034)
World J Surg Oncol. 2020 Jul 20;18(1):176. (PMID: 32690026)
World J Surg Oncol. 2019 Oct 31;17(1):175. (PMID: 31672162)
Cancer Microenviron. 2014 Aug;7(1-2):61-9. (PMID: 24771466)
Cell Death Dis. 2018 Jul 18;9(8):793. (PMID: 30022048)
Semin Cancer Biol. 2018 Oct;52(Pt 2):39-52. (PMID: 28987965)
Cancer. 2000 Apr 1;88(7):1739-57. (PMID: 10738234)
Trends Immunol. 2015 Apr;36(4):229-39. (PMID: 25770924)
Ann Surg Oncol. 2019 Jun;26(6):1613-1621. (PMID: 30927195)
Int J Colorectal Dis. 2020 Jul;35(7):1203-1210. (PMID: 32303831)
J Transl Med. 2007 Nov 29;5:62. (PMID: 18047662)
PLoS One. 2012;7(12):e50946. (PMID: 23284651)
Clin Cancer Res. 2017 Dec 1;23(23):7375-7387. (PMID: 28928161)
Mediators Inflamm. 2016;2016:6058147. (PMID: 26966341)
J Biomed Sci. 2019 Oct 20;26(1):78. (PMID: 31629410)
J Cancer. 2018 Jun 6;9(13):2308-2316. (PMID: 30026826)
Br J Cancer. 2019 Oct;121(8):659-665. (PMID: 31488881)
World J Surg Oncol. 2020 Sep 7;18(1):241. (PMID: 32895059)
World J Surg Oncol. 2018 Jan 16;16(1):9. (PMID: 29338742)
Int J Biol Sci. 2019 Mar 10;15(5):984-998. (PMID: 31182919)
Int J Mol Sci. 2019 Aug 27;20(17):. (PMID: 31461932)
Biomed Pharmacother. 2019 Jul;115:108921. (PMID: 31078045)
PLoS One. 2013 Nov 15;8(11):e80908. (PMID: 24260507)
Cancer Lett. 2017 Feb 28;387:61-68. (PMID: 26845449)
Clin Cancer Res. 2017 Dec 1;23(23):7388-7399. (PMID: 28928159)
J Cancer Res Clin Oncol. 2019 Jul;145(7):1785-1794. (PMID: 31129768)
Mol Cancer. 2019 Mar 30;18(1):64. (PMID: 30927925)
Nature. 2001 Jan 11;409(6817):198-201. (PMID: 11196644)
Cancer Sci. 2013 Apr;104(4):437-44. (PMID: 23298232)
World J Surg Oncol. 2021 Apr 22;19(1):133. (PMID: 33888142)
Contributed Indexing:: Keywords: CD163; Colorectal cancer; Immunohistochemistry; Prognosis; Tumor-associated macrophages
Substance Nomenclature:: 0 (Antigens, CD)
0 (Antigens, Differentiation, Myelomonocytic)
0 (CD163 antigen)
0 (Receptors, Cell Surface)
Entry Date(s):: Date Created: 20210625 Date Completed: 20210628 Latest Revision: 20210701
Update Code:: 20240105
PubMed Central ID:: PMC8229299
DOI:: 10.1186/s12957-021-02299-y
PMID:: 34167561
: Czasopismo naukowe

Pełny tekst

Background: This study aimed to explore the prognostic significance of tumor-associated macrophage (TAM) infiltration in colorectal cancer (CRC) patients.
Methods: Tissue microarray and immunohistochemistry were used to detect the infiltration of CD163+ TAMs in 209 CRC samples, and the Kaplan-Meier method was used for survival analysis. Cox proportional hazards analysis was used for univariate analysis and multivariate analysis of clinically relevant confounders.
Results: The samples were divided into low-level (n = 105) and high-level infiltration groups (n = 104) by the median number of CD163+ TAMs detected. The overall survival (OS) and disease-free survival (DFS) of CRC patients in the low-level CD163+ TAM infiltration group were longer than those in the high-level CD163+ TAM infiltration group (P < 0.001). Infiltration of CD163+ TAMs in CRC tissues was a negative prognostic factor for CRC patients. Risks of death and disease recurrence for CRC patients in the low-level CD163+ TAM infiltration group were lower than those in the high-level CD163+ TAM infiltration group (HR OS = 0.183, 95% CI 0.052-0.647, P = 0.008; HR DFS = 0.191, 95% CI 0.078-0.470, P = 0.000).
Conclusions: The infiltration of CD163+ TAMs in CRC tissue is an independent adverse factor for the prognosis of CRC patients. High-level infiltration of CD163+ TAMs is associated with shorter OS and DFS.

Informacja